Maruho Succeeds Manufacturing and Marketing Approval for Acne Vulgaris Treatment "Epiduo® Gel"
Osaka and Tokyo (Japan), August 1, 2017 - Maruho Co., Ltd. ("Maruho", Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Galderma KK (Head Office: Tokyo, Japan, Representative Director: Leslaw Rudy) announce today that from August 1, 2017, Maruho will succeed the marketing and manufacturing approval in Japan from Galderma KK for acne vulgaris treatment "Epiduo® Gel" (hereinafter referred to as "Epiduo").
Epiduo is a topical formulation of a fixed-dose drug combination containing adapalene and benzoyl peroxide developed by Galderma Pharma S.A. ("Galderma SA", Headquarters: Lausanne, Switzerland, CEO: Stuart Raetzman). Since its first marketing authorization in Europe in 2007, Epiduo has now been approved in 78 countries and areas around the world.
Maruho and Galderma SA agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of Galderma SA's prescription drugs for dermatology in Japan. Maruho has appropriately provided and collected medical information as the distributor of Epiduo in Japan. From August 1, 2017, Maruho will appropriately provide and collect information as the manufacturer and distributor of Epiduo in Japan and will ensure a stable supply of this product.
As a pharmaceutical company specializing in dermatology, Maruho hopes to further contribute to patients suffering from acne vulgaris through the succession of marketing and manufacturing approval for Epiduo in Japan.